Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omni Bio has announced its plans to conduct new trials to test the efficacy of Alpha-1 antitrypsin (AAT) as a treatment in Type 1 diabetes and graft versus host disease (GVHD).
Subscribe to our email newsletter
According to the company, the ability to fund both the Type 1 diabetes and GVHD human clinical trials are subject to the company raising additional capital in the near term.
The company plans to conduct a placebo-controlled Type 1 diabetes human clinical trial in recently diagnosed juvenile subjects.
Omni Bio also intends to initiate a proof of principle human clinical trial for the treatment of lethal complication of bone marrow transplantation.
Omni Bio CEO James Crapo said the plan to complete a placebo-controlled study is next step in its commercial strategy for AAT treatment of recently diagnosed Type 1 diabetics.
"The commencement of a human clinical trial for the treatment or prevention of GVHD is aligned with the treatment of Type 1 diabetes, as both are autoimmune diseases," Crapo added.